Global Biodiversity Fund Stalls as Major Pharmaceutical Companies Face Free-Riding Accusations
A landmark global conservation fund designed to channel corporate profits from nature's genetics into habitat protection has attracted only a fraction of its financial target, drawing sharp criticism toward drug manufacturers.
